NTRK Feb 16, 2022 Rozlytrek Studies Show Durable Responses in Patients With Brain Metastases Premium Feb 11, 2022 Seattle Cancer Care Alliance Aims to Improve Molecular Profiling Access for Thyroid Cancer Patients Premium Feb 4, 2022 CHOP Researchers Find Gene Fusions are Harbingers of Aggressive Disease in Pediatric Thyroid Cancer Premium Dec 14, 2021 AnHeart Raises $61M in Oversubscribed Series B Financing Round Aug 31, 2021 InnoCare Pharma to Launch US Trial of ICP-723 for NTRK Fusion-Positive Solid Cancers Jul 14, 2021 Bayer, OncoDNA, Tamkin Al-Seha Medical Partner to Offer NTRK Fusion Testing in Saudi Arabia Jun 18, 2021 AnHeart Therapeutics Begins Phase II Basket Trial of Taletrectinib in NTRK-Positive Solid Tumors May 28, 2021 Zai Lab Begins Phase II Study of Repotrectinib in NSCLC, Solid Tumors in China May 14, 2021 LUNGevity Aims for Widespread Comprehensive Biomarker Test Access With New Patient-Facing Campaign Premium Jan 27, 2021 CHOP Researchers Urge Broader NTRK Fusion Testing in Pediatric Cancer Patients Premium Jan 5, 2021 Precision Oncology in 2020: Pandemic Lessons, Biomarker Controversies, Community Access Gaps Premium Dec 14, 2020 Daiichi Sankyo, AstraZeneca Begin Phase II Datopotamab Deruxtecan Trial in NSCLC Dec 10, 2020 Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer Nov 10, 2020 HitGen Outlicenses TRK/ROS1 Inhibitor to Baiyunshan for Development in Mainland China Oct 26, 2020 FDA Approves Foundation Medicine CDx, Bayer's Vitrakvi for NTRK Patients Sep 24, 2020 Growing Data on Vitrakvi Demonstrate Enduring Activity Across Variety of NTRK-Positive Tumor Types Premium Sep 3, 2020 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program in Canada Aug 19, 2020 Turning Point's Repotrectinib Yields Promising Early Data in ROS1-, NTRK-Positive Cancers Aug 3, 2020 Roche's Rozlytrek Garners Conditional Authorization in Europe for Cancers With NTRK, ROS1 Fusions Jul 21, 2020 AnHeart Doses First ROS1 Fusion-Positive NSCLC Patient in Phase II Trial of Taletrectinib Load More Breaking News Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager Touchlight to Provide DNA Vector for Odimma Therapeutics' Personalized Neoantigen Vaccine Trial FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Caris Life Sciences, Hummingbird Bioscience Partner on Anti-HER3 Therapy Advancement Akeso, Summit Therapeutics Ink $5B Licensing Deal for PD-1/VEGF Bispecific Antibody Bluestar Genomics to Study Pancreatic Cancer Early Detection Test in Type 2 Diabetes Patients
